Literature DB >> 11403993

Membrane fluidity effects of estratrienes.

Y Liang1, S Belford, F Tang, L Prokai, J W Simpkins, J A Hughes.   

Abstract

Estrogens have demonstrable neuroprotective effects. This fact has lead to the proposed use of estrogens for the prevention and/or treatment of Alzheimer's disease. The exact protective mechanism estrogens provide is not fully understood. In this report, a potential non-genomic mechanism for estratrienes involving alterations in membrane fluidity was studied. Steroids, such as estrogen, are known to be membrane-active and can alter the lipid packing. In this study we used fluorescent methodologies to address the effect of naturally occurring steroids (17alpha and 17beta-estradiol, testosterone, and progesterone) and new estratriene analogs on membrane fluidity using liposomes and HT-22 hippocampal cells. The study's results indicate steroids, based on the estratriene nucleus, can modulate lipid packing as evidenced by (1) decreased membrane fusion events and (2) decreased membrane fluidity. The effects on the membrane were both time and concentration dependent. It was also demonstrated through rational design estratriene analogs can be synthesized with enhanced membrane effects. Finally, in a glutamate-induced toxicity HT-22 model, we also demonstrated cellular protection with the estratriene-based molecules and analogs. The data suggest the plethora of cellular actions of estrogens may relate to or be influenced by membrane effects of the steroid.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403993     DOI: 10.1016/s0361-9230(01)00483-x

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  15 in total

Review 1.  Structure-nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds.

Authors:  Laszlo Prokai; James W Simpkins
Journal:  Pharmacol Ther       Date:  2007-02-02       Impact factor: 12.310

Review 2.  Guarding the blood-brain barrier: a role for estrogen in the etiology of neurodegenerative disease.

Authors:  Farida Sohrabji
Journal:  Gene Expr       Date:  2007

Review 3.  Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury.

Authors:  E B Engler-Chiurazzi; C M Brown; J M Povroznik; J W Simpkins
Journal:  Prog Neurobiol       Date:  2016-02-15       Impact factor: 11.685

4.  Gender differences in renal tubular taurocholate transport.

Authors:  Jan Henrik Schlattjan; Frank Biggemann; Joachim Greven
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-23       Impact factor: 3.000

Review 5.  The assessment of non-feminizing estrogens for use in neuroprotection.

Authors:  Kun Don Yi; Evelyn Perez; Shaohua Yang; Ran Liu; Douglas F Covey; James W Simpkins
Journal:  Brain Res       Date:  2010-11-25       Impact factor: 3.252

6.  Effect of Progesterone, Its Hydroxylated and Methylated Derivatives, and Dydrogesterone on Lipid Bilayer Membranes.

Authors:  Rola Abboud; Hélène Greige-Gerges; Catherine Charcosset
Journal:  J Membr Biol       Date:  2015-04-25       Impact factor: 1.843

Review 7.  Mitochondrial mechanisms of estrogen neuroprotection.

Authors:  James W Simpkins; Kun Don Yi; Shao-Hua Yang; James A Dykens
Journal:  Biochim Biophys Acta       Date:  2009-11-26

8.  Mechanistic investigations on the antioxidant action of a neuroprotective estrogen derivative.

Authors:  Katalin Prokai-Tatrai; Pal Perjesi; Nilka M Rivera-Portalatin; James W Simpkins; Laszlo Prokai
Journal:  Steroids       Date:  2007-11-04       Impact factor: 2.668

9.  Gender differences in cholesterol nucleation in native bile: estrogen is a potential contributory factor.

Authors:  Angela C Brown; Steven P Wrenn; Nandita Suresh; William C Meyers; Mohammad Z Abedin
Journal:  J Membr Biol       Date:  2009-11-07       Impact factor: 1.843

10.  The potential for estrogens in preventing Alzheimer's disease and vascular dementia.

Authors:  James W Simpkins; Evelyn Perez; Xiaofei Wang; Shaohua Yang; Yi Wen; Meharvan Singh
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.